Peter Meredith

Summary

Affiliation: University of Glasgow
Country: UK

Publications

  1. ncbi From hypertension to heart failure -- are there better primary prevention strategies?
    Peter A Meredith
    Department of Medicine and Therapeutics, University of Glasgow, Glasgow, Scotland, UK
    J Renin Angiotensin Aldosterone Syst 7:64-73. 2006
  2. ncbi Benefits of nifedipine GITS in stable coronary artery disease: Further analysis of the "ACTION" database
    Peter A Meredith
    Medicine and Therapeutics, University of Glasgow, Western Infirmary, Glasgow, UK
    Adv Ther 27:297-306. 2010
  3. ncbi Bioequivalence and other unresolved issues in generic drug substitution
    Peter Meredith
    University Department of Medicine and Therapeutics, The Western Infirmary, Glasgow, Scotland, United Kingdom
    Clin Ther 25:2875-90. 2003
  4. ncbi Efficacy and tolerability of long-term rilmenidine treatment in hypertensive diabetic patients. A retrospective analysis of a general practice study
    Peter A Meredith
    Division of Cardiovascular and Medical Sciences, The University of Glasgow, The Western Infirmary, Scotland, UK
    Am J Cardiovasc Drugs 4:195-200. 2004
  5. ncbi Comparison of the efficacy of candesartan and losartan: a meta-analysis of trials in the treatment of hypertension
    P A Meredith
    Department of Medicine and Therapeutics, Division of Cardiovascular and Medical Sciences, Gardiner Institute, Western Infirmary, Glasgow, Scotland, UK
    J Hum Hypertens 24:525-31. 2010
  6. ncbi Potential concerns about generic substitution: bioequivalence versus therapeutic equivalence of different amlodipine salt forms
    Peter A Meredith
    Division of Cardiovascular and Medical Sciences, Department of Medicine and Therapeutics, University of Glasgow, Glasgow, UK
    Curr Med Res Opin 25:2179-89. 2009
  7. ncbi Candesartan cilexetil--a review of effects on cardiovascular complications in hypertension and chronic heart failure
    Peter A Meredith
    Department of Medicine and Therapeutics, University of Glasgow, Western Infirmary, Glasgow, UK
    Curr Med Res Opin 23:1693-705. 2007
  8. ncbi A chronotherapeutic approach to effective blood pressure management
    Peter A Meredith
    Department of Medicine and Therapeutics, University of Glasgow, Western Infirmary, Glasgow, Scotland, GL 116NT United Kingdom
    J Clin Hypertens (Greenwich) 4:15-9. 2002
  9. ncbi Angiotensin II receptor antagonists alone and combined with hydrochlorothiazide: potential benefits beyond the antihypertensive effect
    Peter A Meredith
    Department of Medicine and Therapeutics, Division of Cardiovascular and Medical Science, Gardiner Institute, Glasgow Western Infirmary, Glasgow, UK
    Am J Cardiovasc Drugs 5:171-83. 2005
  10. ncbi Dihydropyridine calcium channel blockers: basic pharmacological similarities but fundamental therapeutic differences
    Peter A Meredith
    Division of Cardiovascular and Medical Sciences, Gardiner Institute, Western Infirmary, Glasgow, Scotland, UK
    J Hypertens 22:1641-8. 2004

Detail Information

Publications15

  1. ncbi From hypertension to heart failure -- are there better primary prevention strategies?
    Peter A Meredith
    Department of Medicine and Therapeutics, University of Glasgow, Glasgow, Scotland, UK
    J Renin Angiotensin Aldosterone Syst 7:64-73. 2006
    ..However, there is now compelling evidence to suggest that this therapy should include an antihypertensive agent that inhibits the reninangiotensin- aldosterone system (RAAS)...
  2. ncbi Benefits of nifedipine GITS in stable coronary artery disease: Further analysis of the "ACTION" database
    Peter A Meredith
    Medicine and Therapeutics, University of Glasgow, Western Infirmary, Glasgow, UK
    Adv Ther 27:297-306. 2010
    ....
  3. ncbi Bioequivalence and other unresolved issues in generic drug substitution
    Peter Meredith
    University Department of Medicine and Therapeutics, The Western Infirmary, Glasgow, Scotland, United Kingdom
    Clin Ther 25:2875-90. 2003
    ..Under these circumstances, measures of individual and population bioequivalence are proposed to be more accurate than measures of average bioequivalence...
  4. ncbi Efficacy and tolerability of long-term rilmenidine treatment in hypertensive diabetic patients. A retrospective analysis of a general practice study
    Peter A Meredith
    Division of Cardiovascular and Medical Sciences, The University of Glasgow, The Western Infirmary, Scotland, UK
    Am J Cardiovasc Drugs 4:195-200. 2004
    ..Recent studies have shown rilmenidine improves glucose tolerance and reduces micro-albuminuria in patients with diabetes mellitus...
  5. ncbi Comparison of the efficacy of candesartan and losartan: a meta-analysis of trials in the treatment of hypertension
    P A Meredith
    Department of Medicine and Therapeutics, Division of Cardiovascular and Medical Sciences, Gardiner Institute, Western Infirmary, Glasgow, Scotland, UK
    J Hum Hypertens 24:525-31. 2010
    ..These findings were consistent when analyses according to dose and combination with HCTZ were carried out. Thus, it can be concluded that at currently recommended doses, candesartan is more effective than losartan in lowering BP...
  6. ncbi Potential concerns about generic substitution: bioequivalence versus therapeutic equivalence of different amlodipine salt forms
    Peter A Meredith
    Division of Cardiovascular and Medical Sciences, Department of Medicine and Therapeutics, University of Glasgow, Glasgow, UK
    Curr Med Res Opin 25:2179-89. 2009
    ..These concerns are illustrated by using the calcium antagonist amlodipine besylate (innovator drug) versus amlodipine maleate (generic), indicated for the treatment of hypertension and angina pectoris, as an example...
  7. ncbi Candesartan cilexetil--a review of effects on cardiovascular complications in hypertension and chronic heart failure
    Peter A Meredith
    Department of Medicine and Therapeutics, University of Glasgow, Western Infirmary, Glasgow, UK
    Curr Med Res Opin 23:1693-705. 2007
    ..The ARB candesartan was initially established as an effective once-daily antihypertensive treatment, providing 24-h blood pressure (BP) control with a trough:peak ratio close to 100%...
  8. ncbi A chronotherapeutic approach to effective blood pressure management
    Peter A Meredith
    Department of Medicine and Therapeutics, University of Glasgow, Western Infirmary, Glasgow, Scotland, GL 116NT United Kingdom
    J Clin Hypertens (Greenwich) 4:15-9. 2002
    ..For example, unlike some other angiotensin II receptor blockers, telmisartan provides consistent reduction of blood pressure during the 24-hour period...
  9. ncbi Angiotensin II receptor antagonists alone and combined with hydrochlorothiazide: potential benefits beyond the antihypertensive effect
    Peter A Meredith
    Department of Medicine and Therapeutics, Division of Cardiovascular and Medical Science, Gardiner Institute, Glasgow Western Infirmary, Glasgow, UK
    Am J Cardiovasc Drugs 5:171-83. 2005
    ..Evidence from these studies suggests a beneficial role beyond the antihypertensive effect of these therapies in providing protection against cardiovascular, renovascular, and cerebrovascular events...
  10. ncbi Dihydropyridine calcium channel blockers: basic pharmacological similarities but fundamental therapeutic differences
    Peter A Meredith
    Division of Cardiovascular and Medical Sciences, Gardiner Institute, Western Infirmary, Glasgow, Scotland, UK
    J Hypertens 22:1641-8. 2004
    ....
  11. ncbi A putative placebo comparison of the SCOPE and LIFE trials
    Peter A Meredith
    Division of Cardiovascular and Medical Sciences, University of Glasgow, Gardiner Institute, Western Infirmary, Scotland, UK
    J Renin Angiotensin Aldosterone Syst 5:59-63. 2004
    ..Neither trial is sufficiently 'powered' to demonstrate a benefit in CHD outcomes, but with SCOPE there was a trend towards benefit with a point estimate compatible with the major meta-analysis...
  12. ncbi Therapy in the elderly hypertensive
    Peter A Meredith
    University Department of Medicine and Therapeutics, The Western Infirmary, Glasgow, G11 6NT, UK. pam
    J Renin Angiotensin Aldosterone Syst 3:S49-56. 2002
  13. ncbi Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program
    Peter A Meredith
    Faculty of Medicine, University of Glasgow, Glasgow, Scotland
    J Am Coll Cardiol 52:2000-7. 2008
    ..40) in the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) program...
  14. ncbi Hematocrit predicts long-term mortality in a nonlinear and sex-specific manner in hypertensive adults
    Laura Paul
    British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom
    Hypertension 60:631-8. 2012
    ..Hypertensive patients with hematocrit levels outside of the sex-specific reference ranges identified in this study should be targeted for more aggressive blood pressure and cardiovascular risk reduction treatment...
  15. ncbi The relationships between initial blood pressure and the response to different antihypertensive agents
    Peter A Meredith
    J Hypertens 25:2513-4; author reply 2514. 2007